BACKGROUND
- BCL2-related anti-apoptotic (BCL-2, BCL-XL, MCL-1, BCL2A1, BCL2L10) and pro-apoptotic proteins (BAX, BAD, BID, BAK-1) regulate cellular sensitivity to apoptosis stimuli 1.
- Overexpression of BCL2 and resistance to apoptosis have been implicated in the development of androgen-independent PCa and disease progression, which has clinical relevance given several therapeutic strategies targeting this pathway 2,3.
- This project aimed to characterize the transcriptomic profile of BCL2-related genes and investigate distinct sensitivity to apoptosis between primary prostate tumors (PT) and metastatic sites (MS).